Sonoma Biotherapeutics is a private drug discovery company. It has raised $265 million across 1 recorded round; the latest was a $265 million Series B in Aug 2021.
PMV mark · valuation
—
Oct 2026
Priced at
—
Total raised
$265.0M
Last round
Early Stage VC (Series B)
Aug 2021
No prints on record
No secondary trades in Sonoma Biotherapeutics shares have been recorded yet. When market activity lands it appears here as monthly aggregates and, for platform-recorded trades, dated prints.
Pro members can request priority coverage with a 48-hour turnaround.
Secondary marks are indicative month-end price levels observed across secondary-market trading venues — a level, not a trade — and are the market input to the PrivateMarketView mark. Private share prices aren’t published anywhere. Aggregate figures combine multiple reporting channels — direct participant reports, platform transactions, third-party market intelligence — at monthly granularity. Individually dated prints are a Pro feature and are shown only for transactions recorded on our own platform. Third-party-reported trades are never republished individually, at any tier. Verified prints (✓) have been confirmed against a second source. Prints marked SPV or Forward reflect the structure’s pricing, which can differ from direct share transfers of Sonoma Biotherapeutics stock.
